Proteomics International Laboratories Ltd

ASX:PIQ ISIN:AU000000PIQ0

Proteomics International Laboratories LtdProteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

 
 
  

View in Other Languages

News

Proteomics International Laboratories Ltd (ASX:PIQ) PromarkerD Licence with Omics Global Extended to Chile

🕔12/20/2023 9:12:03 AM 2620

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce the signing of a licence agreement to expand PromarkerD's reach in Central and South America.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) AGM Chairman's Address and Investor Presentation

🕔11/23/2023 12:22:57 PM 1738

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the Chairman's Address provided by Mr Neville Gardiner and the Investor Presentation provided by Dr Richard Lipscombe to shareholders.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) US Medicare Confirms Reimbursement Price for PromarkerD

🕔11/22/2023 9:13:14 AM 1700

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that the US Centers for Medicare & Medicaid Services has published its final determination of the national reimbursement price in the United States for the PromarkerD predictive test for diabetic kidney disease.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Presents at Bell Potter Healthcare Conference

🕔11/13/2023 9:13:49 AM 1788

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to provide an opportunity for shareholders and investors to view a virtual presentation by Managing Director Dr Richard Lipscombe.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Receives $1.85 Million in R&D Tax Incentive

🕔11/9/2023 9:19:36 AM 1436

Proteomics International Laboratories Ltd (ASX:PIQ) announces that its cash reserves have been further strengthened by the receipt of $1.85 million in research and development tax incentive for the 2022-23 financial year.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Investor Presentation

🕔10/30/2023 9:30:05 AM 1718

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of its latest investor presentation for a non-deal roadshow to institutional investors.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) September 2023 Quarterly Activities Report

🕔10/26/2023 9:10:42 AM 1462

Proteomics International Laboratories Ltd (ASX:PIQ), a medical technology company at the forefront of precision medicine and predictive diagnostics, is pleased to provide the following update on its business activities for the three months to 30 September 2023 and subsequent to the period end.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) International Webinar and Q&A

🕔9/29/2023 3:04:01 PM 2381

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to invite shareholders, investors and interested parties to an online update on the recent announcement regarding the PromarkerD US Reimbursement Price.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) PromarkerD US Reimbursement Price & Aus Regulatory Decision

🕔9/29/2023 9:19:49 AM 1778

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce a major milestone in the commercialisation of its predictive test for diabetic kidney disease, PromarkerD, with the US Centers for Medicare & Medicaid Services.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) New Oesophageal Cancer Test Presented at Global Conference

🕔9/8/2023 8:24:21 AM 1915

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce its latest results for its novel blood test for oesophageal adenocarcinoma will be presented tomorrow at the 19th ISDE World Congress for Esophageal Diseases.

Read Full Article
###

10,623 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 112) (Last 30 Days: 724) (Since Published: 9050) 

Company Data

    Headquarters
  • QEII Medical Centre
    6 Verdun Street
    Nedlands WA 6009
    Australia
  • Telephone
  • +61-8-9389-1992 
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.proteomics.com.au

Company Reports